Limmatech, the GSK spinout focusing on antimicrobial resistance, announced on Monday (9 October) that it has raised $37m in a series A funding round. The round was co-led by Adjuvant Capital, AXA IM Alts and Novo Holdings, the parent company of obesity drugs giant Novo Nordisk.

The company is currently in stage II trials for its Shigella vaccine, which it regained control of from GSK in July of this year. GSK gained the rights to the candidate when it purchased Limmatech’s predecessor, GlycoVaxyn, in 2015. Shigella is a bacteria that causes shigellosis, a diarrheal infection that kills over half a million people each year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Alongside this, the company is working to tackle the problem of antibiotics resistance. LimmaTech CEO Dr Franz-Werner Haas said: “By advancing our innovative technology platform, LimmaTech has the potential to simultaneously provide vaccine-induced protection against bacterial infections, mitigate the increasing risk of antibiotic resistance, and move toward the control of several highly transmissible pathogens.”

By creating vaccines for complex conditions, including gonorrhoea, Limmatech hopes to prevent disease before it happens, which is particularly important for those bacteria that have increased antimicrobial resistance, which is estimated to kill more people than cancer by 2050.

With funding from key institutional investors, as well as the parent of one of the major pharmaceutical success stories of the 21st century, the company’s future looks bright. Camilla Petrycer Hansen, Principal at Novo Holdings and now board member of Limmatech, explained: “With its outstanding record of success in the vaccine field, its seasoned leadership at the helm, and its promising technology, LimmaTech represents a very attractive investment opportunity.”

This deal represents one of the largest that Adjuvant has been involved in this year, second only to the $53m of series E funding raised by Antiva Biosciences to develop novel therapeutics for HPV lesions.

Our signals coverage is powered by GlobalData’s Thematic Engine, which tags millions of data items across six alternative datasets — patents, jobs, deals, company filings, social media mentions and news — to themes, sectors and companies. These signals enhance our predictive capabilities, helping us to identify the most disruptive threats across each of the sectors we cover and the companies best placed to succeed.